Companies

See how salaries can vary from company to company

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinica... view company details

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company, develops therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 that is in Phase II clinical trial for the treatment of critical limb ischemia; CLBS14-CMD, which is in Phase II clinical study to treat coronary microvascular dysfunction; and CLBS14-NORDA that is in Phase III clinical trial for treating no-option refractory disabling angina. The company was formerly known as... view company details

The City of Oxnard is located on the "Gold Coast" of sunny California, approximately halfway between Los Angeles and Santa Barbara, and is known as the gateway to the Channel Islands. Oxnard is a thriving center of commerce, tourism and industry in Ventura County. Oxnard is the largest city in the County with its population of over 200,000 residents. Oxnard services the needs of its culturally diverse population. While the City maintains steady growth with new development, it also promotes the preservation and economic health of its historic downtown. The City also operates more than 50 park f... view company details

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. O... view company details

Nxt-ID, Inc., a security technology company, engages in the development of products and solutions for security, healthcare, financial technology, and Internet of Things (IoT) markets. It offers non-monitored and monitored personal emergency response systems (PERS), including landline and cell-based options; the Fit Pay Trusted Payment Manager Platform (TPMP) that provides IoT and wearable devices with contactless payment capabilities and full digital wallet functionality; World Ventures Flye SmartCard, a smartcard customized for WorldVentures, the travel company; and Fit Pay General Purpose Re... view company details

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic markets. Its non-dermatological formulations offer solutions for women's health, pain management, and others markets. The company offers sunless tanning, anti-aging, and sunscreen products. Skinvisible, Inc. also licenses its products to manufacturers and marketers of brands internationally, as well as sells directly in the... view company details

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331,... view company details

Estes Construction is a leading regional construction manager and general contractor headquartered in downtown Davenport, Iowa. In the last 50 years, the company has evolved by embracing Integrated Project Delivery (IPD), a process that utilizes collaboration to harness the collective input of clients, designers, and the construction team to deliver an exceptional client experience. Estes built its reputation on high standards, satisfied customers, continuous learning, and ongoing personal development view company details

Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier... view company details

Kirwan Surgical Products LLC is dedicated to creating and developing superior products for demanding microsurgical specialties such as ophthalmology, ear, nose and throat, plastic and reconstructive surgery, and orthopaedic surgery. Our mission is to provide innovative high quality products at competitive prices. We continue to be an innovator in the field of electrosurgery, and hold a number of patents on groundbreaking product designs and manufacturing techniques associated with the field. Kirwan Surgical Products is family owned and operated. We were founded in 1979 by Lawrence T. Kirwan Sr... view company details

Cortland is a product-to-people, multifamily real estate investment, development, and management company that in-sources most of its multifamily development, design, construction, renovation, management, and ownership functions - all with the goal of providing residents excellent, hospitality-driven living experiences. With our pioneering business model, our commitment to placing the resident at the center of our decisions, and our enterprising team, we're aiming to set a new experience standard for the apartment industry - one community at a time. Our company is now comprised of a team of mor... view company details

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and i... view company details

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. ... view company details

Diesel Forward is the nation's leading provider of aftermarket diesel engine fuel systems and technical components for light, medium and heavy-duty vehicles and equipment. The company through its Alliant Power brand distribute aftermarket new and remanufactured parts through more than 21 central distributors and over 550 service dealers around the world. Diesel Forward is also the largest distributor of top OEM brands to the aftermarket, including national fleet accounts, through company-owned warehouses across four U.S. time zones. Along with distribution, Diesel Forward operates a fuel syste... view company details

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase ... view company details

SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC. view company details

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine content cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; an... view company details

ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as p... view company details

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment... view company details

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; ... view company details